Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Caremark/AdvancePCS Merger Starts With Streamlining At The Top

  • News

Executive Summary

Caremark Rx President & Chief Operating Officer A.D. Frazier will be leaving the company upon the closing of the AdvancePCS merger

You may also be interested in...



Caremark Will Inherit Antitrust Case Brought By Pharmacists Against PCS

Caremark will assume responsibility for an antitrust case brought by the National Community Pharmacists Association against AdvancePCS upon closing of a merger of the two companies

Caremark Will Inherit Antitrust Case Brought By Pharmacists Against PCS

Caremark will assume responsibility for an antitrust case brought by the National Community Pharmacists Association against AdvancePCS upon closing of a merger of the two companies

Caremark/AdvancePCS Merger Will Give Company Half Medco’s Mail Capacity

Caremark will have about half of Medco's mail-order prescription capacity following the proposed acquisition of AdvancePCS

Table

View full table

Tags:
Latest Headlines

‘Unbalanced’ EU HTA Timelines Exacerbated By Rare Disease & Cancer Drugs

National Drug Stockpiles Create ‘False Sense Of Security’

Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

See All
UsernamePublicRestriction

Register

PS043562

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By